The Vanishing Family

05/04/2025

Love to see families affected by the MAPT gene sharing their stories. Our stories bring us together, and through sharing we find common ground, inspiration, meaning, hope and ACTION.

03/07/2025

Cure MAPT FTD has been granted a patient listening session with the U.S. FDA on May 23, 2025! We will be presenting data about the FTD patient community's preferences related to clinical trials and therapy development. If you are a member of the MAPT FTD patient community (including family members and care partners), please fill out this survey. Thank you for helping to make our FDA Patient Listening Session a success.

12/25/2024

Thank you to the The New York Times for featuring Linde LJ, Cure MAPT FTD and our quest for a cure for familial FTD caused by MAPT genetic mutations on the of today's paper! And thank you to Virginia Hughes for capturing Linde's struggle and bravery so elegantly.

Cure MAPT FTD raises awareness of the MAPT genetic mutation causing FTD, assists a global network of MAPT families, and advocates for trials that will lead to a cure.

12/22/2024

Don't miss this The New York Times article about a true MAPT FTD warrior, Linde LJ, who is fighting day and night for a for .

A mutant gene is coming to steal Linde Jacobs’s mind. Can she find a way to stop it?

12/05/2024

We could not be more excited about this announcement by Switch Therapeutics.

"By the end of 2024, Switch anticipates naming its second development candidate, targeting production of tau, which is directly responsible for neurodegenerative diseases called tauopathies, including primary and secondary tauopathies such as progressive supranuclear palsy and Alzheimer’s disease, among others. Switch’s MAPT program knocks down tau at the genetic level, thus preventing intra-cellular tau production."

https://www.switchthera.com/news/switch-therapeutics-appoints-david-m-holtzman-m-d-to-its-scientific-advisory-board-and-announces-its-first-development-candidate-casi-apoe-a-liver-sparing-apoe-rnai-therapy/

Cure MAPT FTD

Biotech expert and renowned Alzheimer’s disease researcher, David M. Holtzman, M.D., joins Switch’s Scientific Advisory Board to support advancement of company’s novel neurodegenerative pipeline…